PEGASCY Information

Pegascy focuses on the repositioning of abandoned molecules in Phase 2. After an initial success with PegaOne (sold to Centessa Pharmaceutical (Nasdaq:CNTA) in 2021), we are about to launch PegaTwo: a Phase 2 Clinical Trial with our own Bispecific Antibody focusing Pediatric and Female Cancers. More generally, The Pegascy initiative as defined by its founders: “There might be an opportunity to identify recently abandoned molecules to be refocused for a good price after their Pre-Clinical tests if we get together a selected “best in class” college of Researchers which will be able to determine applications to new indications for patients with no effective treatment as of today and, also, who will design new smart Clinical Trial applicable under their responsibility”.